References
- Yazdanbakhsh K. Review: complement receptor 1 therapeutics for prevention of immune hemolysis. Immunohematol 2005;21:109–18.
- Davenport RD. Pathophysiology of hemolytic transfusion reactions. Semin Hematol 2005;42: 165–8.
- Petz LD, Garratty G. Mechanisms of immune hemolysis. In: Petz LD, Garratty G, eds. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone, 2004:133–65.
- Davenport RD. Cytokines as intercellular signals in hemolytic transfusion reactions. Biol Signals 1996; 5:240–5.
- Pineda AA, Brzica SM, Taswell HF. Hemolytic transfusion reaction: recent experience in a large blood bank. Mayo Clin Proc 1978;53:378–90.
- Schirmer DA, Song SC, Baliff JP, et al. Mouse models of IgG- and IgM-mediated hemolysis. Blood 2007; 109:3099–107.
- Ness PM, Shirey RS, Weinstein MH, King KE. An animal model for delayed hemolytic transfusion reactions. Transfus Med Rev 2001;15:305–17.
- Mollison PL. Survival curves of incompatible red cells. An analytical review. Transfusion 1986;26: 43–50.
- Davenport RD, AABB Scientific Section Coordinating Committee. Guidelines for the laboratory evaluation of transfusion reactions. 2003. Bethesda, AABB (pamphlet).
- Standards for blood banks and transfusion services. 22nd ed. Bethesda: AABB, 2003:88–91.
- Petz LD, Garratty G. Hemolytic transfusion reactions. In: Petz LD, Garratty G, eds. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone, 2004:541–72.
- Beauregard P, Blajchman MA. Hemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them. Transfus Med Rev 1994;8:184–99.
- Johnson ST, Fueger JT, Gottschall JL. One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia—a new paradigm. Transfusion 2007;47:697–702.
- Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA 2005;293: 1653–62.
- Duvall CP, Alter HJ, Rath CE. Hemoglobin catabolism following a hemolytic transfusion reaction in a patient with sickle cell anemia. Transfusion 1974;14:382–7.
- Capon SM, Goldfinger D. Acute hemolytic transfusion reaction, a paradigm of the systemic inflammatory response: new insights into pathophysiology and treatment. Transfusion 1995;35:513–20.
- Kellum JA, Decker JM. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29:1526–31.
- Uhl L, Kruskall MS. Complications of transfusion: transfusion reactions and transfusion-transmitted diseases. In: Young N, Gerson S, High K, eds. Clinical hematology. 1st ed. Philadelphia: Mosby, 2006:1272–89.
- Baumgarten R, van Gelder W, van Wintershoven J, Maaskant-Van Wijk PA, Beckers EA. Recurrent acute hemolytic transfusion reactions by antibodies against Doa antigens, not detected by crossmatching. Transfusion 2006;46:244–9.
- Dzik WH. Emily Cooley Lecture 2002: transfusion safety in the hospital. Transfusion 2003;43: 1190–9.
- Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002;42:975–9.
- Sazama K. Transfusion errors: scope of the problem, consequences, and solutions. Curr Hematol Rep 2003;2:518–21.
- Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years’ experience. Transfusion 2000;40: 1207–13.
- Haemovigilance. Vox Sang 2006;90:207–41.
- Brown T. Hemovigilance to biovigilance: an evolution of transfusion safety. Bethesda: AABB, 2007:19–25.